Group 552

Blood Products

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec ac nisi laoreet, aliquet erat sit amet, pellentesque.

Group 552

Blood Products

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec ac nisi laoreet, aliquet erat sit amet, pellentesque.

Group 552

Blood Products

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec ac nisi laoreet, aliquet erat sit amet, pellentesque.

We’re changing the game for researchers

Making it easier to find specimens from diverse patient populations and find even the most “difficult” biospecimens now that the world is your biobank.

Group 345

81%

of researchers limit research due to lack of biospecimens

Group 345

81%

of researchers limit research due to lack of biospecimens

Group 345

81%

of researchers limit research due to lack of biospecimens

Procuring Samples

Providing Specimens

In the News

A Second Life for Specimens Means More Medical Progress

Press Releasess

iSpecimen Unveils Enhanced iSpecimen Marketplace Platform to Help Scientists More Efficiently Find Desired Biospecimens for Research

IPress Releases

iSpecimen Appoints Evan Cox as Vice President of Product Management

IData Sheet

Human Tissue: Richly-Characterized, Ethically-Sourced

Group 578
White Paper

A Worldwide Study of Factors Affecting Sustainable Biobanking

Group 578

Latest News and Events

Featured Resources

Vestibulum euismod convallis odio nec eleifend. Quisque vestibulum, quam quis suscipit ullamcorper, lacus augue elementum lorem, in vehicula augue est in leo. Aliquam id vestibulum dolor. In semper, augue vitae facilisis pellentesque, nisi mi volutpat ipsum, ac accumsan nisl ex vitae velit.
Sed tincidunt lacus rhoncus, ultricies arcu a, auctor lorem. Etiam ac ex sed orci tincidunt dictum. Fusce a accumsan dolor. Pellentesque quam metus,

In a module, you will find an option to enable schema support. Once you enable this option, FAQ schema will be automatically added to your page. In case you are using an external plugin to add schema you can keep it disabled.

The module follows Google guidelines and adds FAQ schema.

In the News

How Medical Researchers Can Leverage Tech to Help Streamline Biospecimen Matchmaking and Procurement

Many medical advancements – from life-saving vaccines and treatments to new diagnostic tests like liquid biopsies – are built on research that involves human biospecimens.

In the News

How Medical Researchers Can Leverage Tech to Help Streamline Biospecimen Matchmaking and Procurement

Many medical advancements – from life-saving vaccines and treatments to new diagnostic tests like liquid biopsies – are built on research that involves human biospecimens.

This is tab content. Click to edit this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

This is tab content. Click to edit this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Group 503

Christopher Ianelli, MD, PhD

Founder and Chief Executive Officer

Group 503

Christopher Ianelli, MD, PhD

Founder and Chief Executive Officer

Chris conceptualized and founded iSpecimen in response to the precision medicine movement and the growing demand for biospecimens by life science researchers. As CEO, he is responsible for the company’s growth, performance, and corporate direction. Under his leadership, iSpecimen has become a dominant player in research sample procurement, recently developing and launching the industry’s first and only true marketplace platform connecting researchers with healthcare providers and biorepositories.

Prior to launching iSpecimen, Chris served as Managing Director at Leerink Partners (formerly Leerink Swann), a leading healthcare and life science investment bank, where he managed the expansion and delivery of services and directed strategy to develop new healthcare data and information assets for the firm. At Leerink, Chris launched Health Insight Technologies, a healthcare informatics company that was spun out of the firm as Humedica and acquired by UnitedHealth Group in 2013.

Prior to Leerink, Chris was a co-founder and Managing Director of Boston Medical & Scientific Advisors, a healthcare investment research firm ultimately acquired by Leerink. He received both his Ph.D. in Immunology and his M.D. from Tufts University and completed his residency training, including a year as Chief Resident, in Pathology at Brigham & Women’s Hospital and Harvard Medical School.

Andrew Ross

Board Member

defualt_thumbnail_img

Reaching Across Continents: A Prospective Biospecimen Collection Case Study

defualt_thumbnail_img

Plastic is everywhere, including our bloodstreams

Plastics are ubiquitous in the developed world, and scientists have long known that humans breathe and inadvertently...

 

Video Transcription

Video Transcription

Video Transcription

Video Transcription

Video Transcription

Video Transcription

ValidationTesting

2019-01-01

Heading 1

I am timeline card content. You can change me anytime. Click here to edit this text.

2020-01-01

Heading 2

I am timeline card content. You can change me anytime. Click here to edit this text.

2021-01-01

Heading 3

I am timeline card content. You can change me anytime. Click here to edit this text.

Info Box

Enter description text here. Lorem ipsum dolor sit amet, consectetur adipiscing. Quo incidunt ullamco.

Cash $9,790,732 $695,909
Accounts receivable - unbilled 1,750,744 652,761
Accounts receivable, net of allowance for doubtful accounts of $141,952 and $108,096 at September 30, 2021 and December 31, 2020, respectively 2,718,682 1,526,392
Inventory - -
Prepaid expenses and other current assets 459,321 417,929
Tax credit receivable, current portion 179,376 179,376
Total current assets 14,898,855 3,472,367
Property and equipment, net 44,749 75,589
Internally developed software, net 2,650,867 2,634,139
Tax credit receivable, net of current portion - -
Security deposits 27,601 27,601
Total assets $17,622,072 $6,209,696
Current liabilities
Accounts payable $351,424 $1,792,432
Accrued expenses 1,025,136 810,910
Accrued interest 7,510 3,696,944
Convertible notes payable, related parties, net of unamortized debt discount and debt issuance costs - 5,490,811
Derivative liability for embedded conversion features on convertible notes payable - 2,373,000
Bridge notes payable, net of debt issuance costs - 4,589,228
Bridge notes payable, related parties - 1,905,000
Note payable, current portion - 604,109
Deferred revenue 718,723 873,254
Total current liabilities 2,102,793 22,135,688
Note payable, net of current portion - 178,899
Term loan 3,428,380 -
Total liabilities 5,531,173 22,314,587
Commitments and contingencies
Series B convertible preferred stock, $0.0001 par value, 3,200,000 shares authorized, 0 and 572,465 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively - 7,999,997
Series A-1 convertible preferred stock, $0.0001 par value, 556,550 shares authorized, 0 and 100,365 issued and outstanding at September 30, 2021 and December 31, 2020, respectively - 561,041
Series A convertible preferred stock, $0.0001 par value, 3,427,871 shares authorized, 0 and 618,182 issued and outstanding at September 30, 2021 and December 31, 2020, respectively - 2,612,038
Total convertible preferred stock - 11,173,076
Stockholders' equity (deficit)
Common stock, $0.0001 par value, 200,000,000 shares authorized, 6,996,758 issued, and 6,965,758 outstanding at September 30, 2021, and 16,000,000 shares authorized, 967,213 issued and 936,213 outstanding at December 31, 2020 697 94
Additional paid-in capital 48,059,389 1,779,698
Treasury stock, 31,000 shares at September 30, 2021 and December 31, 2020, at cost (172) (172)
Accumulated deficit (35,969,015) (29,057,587)
Total stockholders' equity (deficit) 12,090,899 (27,277,967)
Total liabilities, convertible preferred stock and stockholders' equity (deficit) $17,622,072 $6,209,696
2021 2020 2021 2020
Revenue $2,718,534 $2,250,147 $8,586,217 $5,466,375
Operating expenses:
Cost of revenue 913,833 903,862 4,026,680 2,032,111
Technology 543,581 413,381 1,315,331 1,131,695
Sales and marketing 513,107 506,641 1,690,085 1,305,897
Supply development 171,595 133,007 383,864 395,200
Fulfillment 399,145 241,785 955,516 642,140
General and administrative 1,636,346 774,550 4,144,989 1,431,262
Total operating expenses 4,177,607 2,973,226 12,516,465 6,938,305
Loss from operations (1,459,073) (723,079) (3,930,248) (1,471,930)
Other expense, net Interest expense (75,922) (469,477) (2,062,548) (1,517,697)
Change in fair value of derivative liability on convertible notes (54,000) (271,000) (76,000)
Change in fair value of derivative liability on bridge notes and bridge notes, related parties 1,582,700
Gain (loss) on extinguishment of bridge notes and bridge notes, related parties (2,740,425)
Loss on extinguishment of convertible notes and convertible notes, related parties (260,185)
Gain on extinguishment of note payable 788,156
Other expense, net (21,687) (21,756) 6,691
Interest income 3,659 87 3,878 396
Other expense, net (93,950) (523,390) (2,981,180) (1,586,610)
Income (loss) before benefit from income taxes (1,553,023) (1,246,469) (6,911,428) (3,058,540)
Benefit from income taxes
Net income (loss) $ (1,553,023) $(1,246,469) $(6,911,428) $(3,058,540)
Net income (loss) per share
Basic and diluted $(0.22) $(1.33) $(2.17) $(3.27)
Weighted average common shares outstanding
Basic and diluted 6,960,330 936,213 3,190,060 936,213
Company Contact Country
Alfreds Futterkiste Maria Anders Germany
Centro comercial Moctezuma Francisco Chang Mexico
Ernst Handel Roland Mendel Austria
Island Trading Helen Bennett UK
Laughing Bacchus Winecellars Yoshi Tannamuri Canada
Magazzini Alimentari Riuniti Giovanni Rovelli Italy